Clinical Trial Update: Dapagliflozin in PRESERVED Ejection Fraction Heart Failure [Phase 4]

View source ↗

Summary

Phase 4 trial update for dapagliflozin in chronic heart failure with preserved ejection fraction has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Systolic Function

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Saint Luke's Health System | Conditions: Chronic Heart Failure With Preserved Systolic Function | Phase 4 | Status: COMPLETED | Results posted: 2022-10-19